Treatment options and treatments for neurodegenerative disorders

Abstract

The present disclosure provides methods for individualizing and monitoring treatment with a neurodegenerative therapeutic agent, such as sigma-1 receptor agonist therapy, in a subject based on pre- and post-treatment gene expression changes. The present disclosure also provides methods for assessing a subject's current status or risk of developing a neurodegenerative disorder. Kits for carrying out the methods are also provided.

Images